Karyopharm Therapeutics Inc.
KPTIQ· OTC
Released Aug 6, 2024, before the open
10-Q filed Aug 6, 2024, 37 days after period end · 0000950170-24-091210
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $42.79M | $37.58M | $39.68M | $22.60M |
| Net Income | $23.79M | -$32.63M | -$49.06M | -$53.58M |
| EPS Diluted |
Karyopharm Therapeutics Inc. · CIK 1503802 · Engraved from SEC EDGAR
| -$2.97 |
| -$0.29 |
| -$0.62 |
| -$0.71 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.